Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Hold” by Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have received an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $15.6667.

A number of equities research analysts have recently weighed in on the stock. TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective for the company. in a report on Monday, December 22nd. Leerink Partners cut shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $17.00 to $14.50 in a research report on Monday. Citigroup restated a “neutral” rating and set a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Monday, December 22nd. Cantor Fitzgerald downgraded Amicus Therapeutics from an “overweight” rating to a “hold” rating and decreased their price objective for the stock from $21.00 to $14.50 in a report on Friday, December 19th. Finally, Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th.

Insider Buying and Selling

In other news, CEO Bradley L. Campbell sold 77,926 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $10.86, for a total transaction of $846,276.36. Following the completion of the sale, the chief executive officer owned 1,129,782 shares of the company’s stock, valued at approximately $12,269,432.52. This represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Michael Clark sold 25,642 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $14.17, for a total transaction of $363,347.14. Following the completion of the transaction, the insider owned 245,690 shares in the company, valued at $3,481,427.30. This represents a 9.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 345,450 shares of company stock worth $3,657,000. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. FNY Investment Advisers LLC bought a new stake in shares of Amicus Therapeutics in the third quarter worth about $43,000. Tudor Investment Corp ET AL raised its position in Amicus Therapeutics by 5.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 168,984 shares of the biopharmaceutical company’s stock valued at $1,332,000 after purchasing an additional 9,487 shares during the last quarter. Allworth Financial LP lifted its holdings in Amicus Therapeutics by 36.3% in the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,246 shares during the period. Swiss Life Asset Management Ltd purchased a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $83,000. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $234,000.

Amicus Therapeutics Price Performance

FOLD opened at $14.25 on Wednesday. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $4.40 billion, a P/E ratio of -356.16 and a beta of 0.46. The stock has a 50-day moving average price of $10.32 and a 200-day moving average price of $8.25. Amicus Therapeutics has a 12-month low of $5.51 and a 12-month high of $14.36.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. The company had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.Amicus Therapeutics’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. Equities analysts predict that Amicus Therapeutics will post 0.15 earnings per share for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.